Guardant Health, Inc. (GH) Social Stream
Featured Post From StockTwits About GH
$GH We believe Guardant Health's underperformance in the second quarter resulted from two factors. First, the company generated solid but unexciting results for the first quarter, which included only modestly beating expectations and only reiterating its fullyear guidance. Given the company's premium valuation, the results were not strong enough to support Guardant's share price. Second, Guardant Health outperformed high growth Tools & Diagnostics companies in the first quarter and there was likely a mean reversion dynamic at play in the most recent quarter.BioTechHedge, published August 14, 2021
We continue to have high conviction in Guardant Health with the company positioned to potentially benefit from multiple trial updates, including for Guardant Reveal and LUNAR-2, and several reimbursement decisions. We believe the company is also positioned to build additional momentum in its core business with the decline of Covid-19 cases in the U.S."